Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
作者信息
Stinchcombe Thomas E, Ramalingam Suresh S
出版信息
Lancet Oncol. 2010 Jun;11(6):500-1. doi: 10.1016/S1470-2045(10)70120-0. Epub 2010 May 20.
Abstract
摘要
相似文献
1
Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Lancet Oncol. 2010 Jun;11(6):500-1. doi: 10.1016/S1470-2045(10)70120-0. Epub 2010 May 20.
2
Clairvoyance or reliable prediction of the future?
Ann Oncol. 2007 Mar;18(3):407-8. doi: 10.1093/annonc/mdl503.
3
NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
Lancet Oncol. 2012 Aug;13(8):764-5. doi: 10.1016/s1470-2045(12)70296-6.
4
Molecular selection trumps clinical selection.
J Clin Oncol. 2011 Jul 20;29(21):2843-4. doi: 10.1200/JCO.2011.35.9208. Epub 2011 Jun 13.
5
Personalized medicine and inhibition of EGFR signaling in lung cancer.
N Engl J Med. 2009 Sep 3;361(10):1018-20. doi: 10.1056/NEJMe0905763. Epub 2009 Aug 19.
6
Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.
Clin Lung Cancer. 2005 Jan;6(4):214-6. doi: 10.1016/s1525-7304(11)70473-9.
7
Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
Nat Rev Clin Oncol. 2010 Nov;7(11):618-9. doi: 10.1038/nrclinonc.2010.168.
8
Medical treatment of non-small-cell lung cancer.
Ann Oncol. 2005;16 Suppl 2:ii229-32. doi: 10.1093/annonc/mdi721.
9
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
J Clin Oncol. 2008 Mar 1;26(7):1182-4; author reply 1184-6. doi: 10.1200/JCO.2007.14.9039.
10
Histology matters: individualizing treatment in non-small cell lung cancer.
Oncologist. 2010;15(1):3-5. doi: 10.1634/theoncologist.2009-0306. Epub 2010 Jan 19.
Zotero 插件